RT Journal Article
SR Electronic
T1 Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.24.21252047
DO 10.1101/2021.02.24.21252047
A1 Mariën, Joachim
A1 Michiels, Johan
A1 Heyndrickx, Leo
A1 Nkuba-Ndaye, Antoine
A1 Ceulemans, Ann
A1 Bartholomeeusen, Koen
A1 Madinga, Joule
A1 Mbala-Kingebeni, Placide
A1 Vanlerberghe, Veerle
A1 Ahuka-Mundeke, Steve
A1 Wang, Lin-Fa
A1 Ariën, Kevin K.
YR 2021
UL http://medrxiv.org/content/early/2021/02/25/2021.02.24.21252047.abstract
AB High-throughput serological tests that can detect neutralizing antibodies against SARS-CoV-2 are desirable for serosurveillance and vaccine efficacy evaluation. Although the conventional neutralization test (cVNT) remains the gold standard to confirm the presence of neutralizing antibodies in sera, the test is too labour-intensive for massive screening programs and less reproducible as live virus and cell culture is involved. Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPass™) that can be done without biosafety level 3 containment in less than 2 hours. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94% (CI 90-96%) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 89% (CI 81-93%) on a panel of 184 healthcare workers from the Democratic Republic of Congo. We also found strong antibody titer correlations (rs>0.8) among the different techniques used. In conclusion, our evaluation suggests that the sVNT could be a powerful tool to monitor/detect neutralising antibodies in cohort and population studies. The technique could be especially useful for vaccine evaluation studies in sub-Saharan Africa where the basic infrastructure to perform cVNTs is lacking.Competing Interest StatementL-FW is a co-inventor on a patent application for the sVNT technology and a commercial kit, cPassTM, is being marketed by GenScript Biotech. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Clinical TrialNAFunding StatementThe work was funded by a European & Developing Countries Clinical Trials Partnership (EDCTP) project (Africover: RIA2020EF-3031), the Research Foundation Flanders (FWO) (G0G4220N and G054820N), the Health Care Worker seroprevalence study (Sciensano/ITM), NCT04373889 and intramural funds from the Institute of Tropical Medicine Antwerp. Joachim Marien is currently a research assistant of Research Foundation Flanders (FWO) and Antoine Nkuba received a doctoral scholarship from the French Institut de Recherche pour le Developpement. Work at Duke-NUS is supported by Singapore National Research Foundation (NRF2016NRF-NSFC002-013) and National Medical Research Council (STPRG-FY19-001 and COVID19RF-003). The Congo study was conducted with funding from Enabel (the Belgian Development agency), GIZ (Deutsche Gesellschaft fur Internationale Zusammenarbeit) and the framework agreement between the Institute of Tropical Medicine and the Belgian Development Cooperation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to sample from Belgian COVID-19 cases was given by the institutional review boards of the University of Ghent, the University Hospital Antwerp and Jessa Hospital Hasselt. Ethical clearance to use samples for the evaluation of the test was given by the Institutional Review board of the Institute of Tropical Medicine Antwerp. For the Congolese samples, ethical approval was given by Institutional Review board of the Institute of Tropical Medicine Antwerp and the National Reference Laboratory INRB in Kinshasa (DRC). All participants provided informed consent to participate. We declare that the planning conduct and reporting of the study was in line with the Declaration of Helsinki, as revised in 2013.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding or last author on reasonable request.